rofecoxib has been researched along with Coxarthrosis in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rofecoxib 25 mg was significantly better than celecoxib 200 mg in relieving night pain at 6 weeks in one study; this was not confirmed in the accompanying study." | 6.72 | Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. ( Polis, AB; Rubin, BR; Schnitzer, TJ; Smugar, SS; Tershakovec, AM; Weaver, AL, 2006) |
| "5), with symptomatic osteoarthritis of hip or knee were included in an open label study with rofecoxib." | 5.11 | Responsiveness of the electronic touch screen WOMAC 3.1 OA Index in a short term clinical trial with rofecoxib. ( Bellamy, N; Bischoff-Ferrari, HA; Good, M; Theiler, R, 2004) |
| "Rofecoxib 25 mg was significantly better than celecoxib 200 mg in relieving night pain at 6 weeks in one study; this was not confirmed in the accompanying study." | 2.72 | Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. ( Polis, AB; Rubin, BR; Schnitzer, TJ; Smugar, SS; Tershakovec, AM; Weaver, AL, 2006) |
| "Rofecoxib and naproxen were generally well tolerated." | 2.70 | Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration. ( Amante, C; Chen, SL; Choon, D; Chow, CT; De Tora, L; Genti, G; Laurenzi, M; Lu, HS; Moan, A; Myllykangas-Luosujärvi, R; Pasero, G; Rodgers, DB; Sarembock, B; Vrijens, F; Zerbini, CA, 2002) |
| "Rofecoxib was well tolerated and provided efficacy that was clinically comparable, according to predefined statistical criteria, to that of 150 mg of diclofenac per day in this 1-year study." | 2.69 | Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 ( Bolognese, J; Caldwell, JR; Cannon, GW; Daniels, B; Ehrich, E; Holt, P; McLean, B; Mukhopadhyay, S; Seidenberg, B, 2000) |
| "Rofecoxib was recalled in September 2004 when studies identified increased cardiovascular risk compared with placebo among patients taking rofecoxib." | 1.33 | The patient's perspective on the recall of Vioxx. ( Hawker, GA; Katz, JN; Solomon, DH, 2006) |
| " Adverse events were closely monitored." | 1.32 | Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients. ( Bannwarth, B; Dougados, M; Euller-Ziegler, L; Ravaud, P; Rolland, D; Trèves, R, 2003) |
| "Rofecoxib is a highly selective inhibitor of cyclooxygenase-2 used in symptomatic treatment of inflammation and pain in patients with osteoarthritis of the hip or knee." | 1.31 | Rofecoxib improves quality of life in patients with hip or knee osteoarthritis. ( Bischoff, HA; Good, M; Theiler, R; Uebelhart, D, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Myllykangas-Luosujärvi, R | 1 |
| Lu, HS | 1 |
| Chen, SL | 1 |
| Choon, D | 1 |
| Amante, C | 1 |
| Chow, CT | 1 |
| Pasero, G | 1 |
| Genti, G | 1 |
| Sarembock, B | 1 |
| Zerbini, CA | 1 |
| Vrijens, F | 1 |
| Moan, A | 1 |
| Rodgers, DB | 1 |
| De Tora, L | 1 |
| Laurenzi, M | 1 |
| Bannwarth, B | 1 |
| Trèves, R | 1 |
| Euller-Ziegler, L | 1 |
| Rolland, D | 1 |
| Ravaud, P | 1 |
| Dougados, M | 1 |
| Theiler, R | 2 |
| Bischoff, HA | 1 |
| Good, M | 2 |
| Uebelhart, D | 1 |
| Bischoff-Ferrari, HA | 1 |
| Bellamy, N | 1 |
| Hawker, GA | 1 |
| Katz, JN | 1 |
| Solomon, DH | 1 |
| Smugar, SS | 1 |
| Schnitzer, TJ | 1 |
| Weaver, AL | 1 |
| Rubin, BR | 1 |
| Polis, AB | 1 |
| Tershakovec, AM | 1 |
| Cannon, GW | 1 |
| Caldwell, JR | 1 |
| Holt, P | 1 |
| McLean, B | 1 |
| Seidenberg, B | 1 |
| Bolognese, J | 1 |
| Ehrich, E | 1 |
| Mukhopadhyay, S | 1 |
| Daniels, B | 1 |
| Adler, J | 1 |
4 trials available for rofecoxib and Coxarthrosis
| Article | Year |
|---|---|
Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration.
Topics: Aged; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adminis | 2002 |
Responsiveness of the electronic touch screen WOMAC 3.1 OA Index in a short term clinical trial with rofecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Computer Terminals; Female; Hip Joint; Humans; Knee J | 2004 |
Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Double-Blind Method; Female; Humans; Lactones; Male; Midd | 2006 |
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Double- | 2000 |
4 other studies available for rofecoxib and Coxarthrosis
| Article | Year |
|---|---|
Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients.
Topics: Administration, Oral; Aged; Ambulatory Care; Cyclooxygenase Inhibitors; Drug Administration Schedule | 2003 |
Rofecoxib improves quality of life in patients with hip or knee osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Lactones; Male; Middle Aged; Osteoart | 2002 |
The patient's perspective on the recall of Vioxx.
Topics: Aged; Cardiovascular Diseases; Communication; Cyclooxygenase 2 Inhibitors; Drug and Narcotic Control | 2006 |
Arthritis: what it is, why you get it and how to stop the pain.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Celecoxib; Cyclooxy | 2001 |